Kalaris Therapeutics, Inc. (KLRS)

NASDAQ: KLRS · Real-Time Price · USD
2.690
+0.010 (0.37%)
At close: Aug 1, 2025, 4:00 PM
2.690
0.00 (0.00%)
After-hours: Aug 1, 2025, 4:00 PM EDT
0.37%
Market Cap50.22M
Revenue (ttm)n/a
Net Income (ttm)-75.96M
Shares Out 18.70M
EPS (ttm)-10.39
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume52,807
Open2.720
Previous Close2.680
Day's Range2.560 - 2.750
52-Week Range2.280 - 24.150
Betan/a
AnalystsBuy
Price Targetn/a
Earnings DateAug 15, 2025

About KLRS

Kalaris Therapeutics, Inc., a clinical-stage ophthalmology biotech company, engages in developing therapies for the treatment of neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was incorporated in 2019 and is based in Palo Alto, California. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2019
Employees 14
Stock Exchange NASDAQ
Ticker Symbol KLRS
Full Company Profile

Financial Performance

Financial Statements

News

Kalaris to Present at Noble Capital Markets 2025 Emerging Growth Equity Conference

PALO ALTO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercializatio...

2 months ago - GlobeNewsWire

Kalaris to Participate at Stifel Ophthalmology Forum

PALO ALTO, Calif., May 23, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization...

2 months ago - GlobeNewsWire

Kalaris Reports First Quarter 2025 Financial Results and Provides Business Highlights

Actively enrolling nAMD patients in a Phase 1 trial of TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovasc...

2 months ago - GlobeNewsWire

Kalaris Expands Board of Directors Appointing Leone Patterson as Chair of Audit Committee

Highly experienced biotech executive and board member will assist Kalaris in achieving its next phase of growth Highly experienced biotech executive and board member will assist Kalaris in achieving i...

4 months ago - GlobeNewsWire

Kalaris Announces Closing of Merger with AlloVir

Kalaris is focused on developing TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovascular and exudative dis...

Other symbols: ALVR
4 months ago - GlobeNewsWire